The Pharmalot View

The Pharmalot View Ed Silverman

Take a deep breath: Asthma drug study failed to include Black and Puerto Rican children who could benefit most

The Pharmalot View Ed Silverman

‘Remember her as the badass she was’: ALS patient who died should force Biogen, others to anticipate expanded access issues

The Pharmalot View Ed Silverman

Biden wants to bolster the pharma supply chain. A major generic plant closing may make that harder

The Pharmalot View Ed Silverman

Too close for comfort: FDA shouldn’t loosen conflict rules for its expert panels

The Pharmalot View Ed Silverman

By looking the other way, pharma money helped fuel a toxic political atmosphere in the U.S.

The Pharmalot View Ed Silverman

‘Where is Rudy?’: Inside Giuliani’s checkered track record as a pharma consultant

The Pharmalot View Ed Silverman

FDA commissioner needs to push back and tell Trump the agency is not part of the ‘deep state’

The Pharmalot View Ed Silverman

Operation Warp Speed doesn’t have the transparency it needs

The Pharmalot View Ed Silverman

We shouldn’t rush to use an unproven malaria drug to treat the coronavirus

The Pharmalot View Ed Silverman

The FDA commissioner sweepstakes: Is Azar yearning to get out of Gottlieb’s shadow?

The Pharmalot View Ed Silverman

Grandstanding, not real change: Why drug prices in TV ads will be confusing and irrelevant

The Pharmalot View Ed Silverman

Kapoor certainly deserves to go to jail, but so do some other pharma execs

The Pharmalot View Ed Silverman

If the states don’t treat pharma as a utility, it may be ‘lights out’ for too many patients

The Pharmalot View Ed Silverman

Forget about an international pricing index for drugs. Cost-effectiveness is a better bargain

The Pharmalot View Ed Silverman

Tweet this: Gottlieb’s leaving, and so is FDA’s highly effective communicator

The Pharmalot View Ed Silverman

Prepare for grilling: 7 questions for 7 pharma execs who’ll testify before Congress about prices

The Pharmalot View Ed Silverman

The military pushed it for the battlefield. The FDA went along. Is the newest opioid any better?

The Pharmalot View Ed Silverman

The list price is not right: Trump’s plan to force pharma to advertise prices is misguided

The Pharmalot View Ed Silverman

One of the world’s largest drug makers is paying docs again — and patients are the worse off

The Pharmalot View Ed Silverman

From zero to hero: J&J CEO praises Trump one year after chastising him

The Pharmalot View Ed Silverman

When modest is actually excessive: AstraZeneca spins its price hikes

The Pharmalot View Ed Silverman

He can shame Pfizer and others, but Trump doesn’t have a practical way to lower drug prices

The Pharmalot View Ed Silverman

Novartis’ tone-deaf response to Michael Cohen: troubling, but not surprising

The Pharmalot View Ed Silverman

Sanofi scandal in the Philippines could spread dangerous mistrust of vaccines

The Pharmalot View Ed Silverman

The Pharmalot View

Most Read

‘Deeply problematic’: AmerisourceBergen rewards its CEO despite the ravages of the opioid crisis

Oh, the irony! Trump may like to vilify drug makers, but now he needs them more than ever

‘Everyone was left to guess what went wrong’: An open letter to AstraZeneca’s CEO on transparency

Pharma drew a line in the sand over Covid-19 vaccine readiness — because someone had to

Where’s the data? In a pandemic, now is no time to sit on Covid-19 trial results

Azar has a ‘tin ear’ when it comes to pricing a potential coronavirus treatment

Memo to the Novartis CEO: When in doubt, give the FDA a heads-up

Trump proposes importing medicines, but he’s really seeking a quick political hit

All Coverage

Take a deep breath: Asthma drug study failed to include Black and Puerto Rican children who could benefit most

‘Remember her as the badass she was’: ALS patient who died should force Biogen, others to anticipate expanded access issues

Biden wants to bolster the pharma supply chain. A major generic plant closing may make that harder

Too close for comfort: FDA shouldn’t loosen conflict rules for its expert panels

By looking the other way, pharma money helped fuel a toxic political atmosphere in the U.S.

‘Where is Rudy?’: Inside Giuliani’s checkered track record as a pharma consultant

FDA commissioner needs to push back and tell Trump the agency is not part of the ‘deep state’

Operation Warp Speed doesn’t have the transparency it needs

We shouldn’t rush to use an unproven malaria drug to treat the coronavirus

The FDA commissioner sweepstakes: Is Azar yearning to get out of Gottlieb’s shadow?

Grandstanding, not real change: Why drug prices in TV ads will be confusing and irrelevant

Kapoor certainly deserves to go to jail, but so do some other pharma execs

If the states don’t treat pharma as a utility, it may be ‘lights out’ for too many patients

Forget about an international pricing index for drugs. Cost-effectiveness is a better bargain

Tweet this: Gottlieb’s leaving, and so is FDA’s highly effective communicator

Prepare for grilling: 7 questions for 7 pharma execs who’ll testify before Congress about prices

The military pushed it for the battlefield. The FDA went along. Is the newest opioid any better?

The list price is not right: Trump’s plan to force pharma to advertise prices is misguided

One of the world’s largest drug makers is paying docs again — and patients are the worse off

From zero to hero: J&J CEO praises Trump one year after chastising him

When modest is actually excessive: AstraZeneca spins its price hikes

He can shame Pfizer and others, but Trump doesn’t have a practical way to lower drug prices

Novartis’ tone-deaf response to Michael Cohen: troubling, but not surprising

Sanofi scandal in the Philippines could spread dangerous mistrust of vaccines

The Pentagon wants to approve drugs for the battlefield. Here’s why that’s dangerous

You've been selected! STAT+ for less than $2/day

Subscribe to STAT+ for less than $2 per day